# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2020

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2020-08-06
- Accepted by EDGAR: Aug 6, 2020, 16:22 ET
- Period: 2020-06-30
- Accession: 0001723128-20-000013
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000172312820000013/amrx-20200630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000172312820000013/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-01 to 2020-06-30 | $464.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2020-01-01 to 2020-06-30 | $963.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-04-01 to 2020-06-30 | $319.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2020-01-01 to 2020-06-30 | $633.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-04-01 to 2020-06-30 | $144.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2020-01-01 to 2020-06-30 | $327.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-04-01 to 2020-06-30 | $45.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2020-01-01 to 2020-06-30 | $82.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-04-01 to 2020-06-30 | $80.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2020-01-01 to 2020-06-30 | $158.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-04-01 to 2020-06-30 | $10.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-01-01 to 2020-06-30 | $68.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-04-01 to 2020-06-30 | $2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-01-01 to 2020-06-30 | −$106.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-04-01 to 2020-06-30 | −$12.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-01-01 to 2020-06-30 | $103.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-04-01 to 2020-06-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2020-01-01 to 2020-06-30 | $0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-04-01 to 2020-06-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2020-01-01 to 2020-06-30 | $0.70 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-04-01 to 2020-06-30 | 147,392,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2020-01-01 to 2020-06-30 | 148,309,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2020-01-01 to 2020-06-30 | $228.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-01 to 2020-06-30 | $15.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-06-30 | $266.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-30 | $1.48bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-30 | $4.06bn | us-gaap:Assets |
| Current liabilities | at 2020-06-30 | $655.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2020-06-30 | $2.76bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-06-30 | $29.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2020-06-30 | $306.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 55,119 characters.

Amneal Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic pharmaceutical products across a broad array of dosage forms and therapeutic areas, as well as branded products. We were formed on October 4, 2017, under the name Atlas Holdings, Inc. for the purpose of facilitating the combination (the "Combination") of Impax Laboratories, Inc. ("Impax") and Amneal Pharmaceuticals LLC ("Amneal"), which closed on May 4, 2018.

The following discussion and analysis for the three and six months ended June 30, 2020 should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2019 included in our 2019 Annual Report on Form 10-K.

On January 31, 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). As a result of the AvKARE, LLC and R&S acquisitions (the “Acquisitions”), we now have three reportable segments, Generics, Specialty, and AvKARE.

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system ("CNS") disorders, including migraine and Parkinson’s disease. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio includes Zomig® (zolmitriptan) products, for the treatment of migraine headaches, which is sold under a license agreement with AstraZeneca U.K. Limited, Emverm® (mebendazole) 100 mg chewable tablets, for the treatment of pinworm, whipworm, common roundworm, common hookworm and American hookworm in single or mixed infections, and Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with JSP.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

Our Generics segment includes approximately 250 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions), films, transdermal patches and topicals (which are creams or gels designed to administer pharmaceuticals locally through the skin). We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and pricing of the affected products. Additionally, pricing is often affected by factors outside of the Company’s control.

AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, as well as medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States of America focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our *2019 Annual Report on Form 10-K,* as supplemented by Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q.

#### COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of

COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of non-essential services. These measures, though currently temporary in nature, may become more severe and continue indefinitely depending on the evolution of the outbreak.

The Company did not observe significant impacts on its business or results of operations for the three months ended March 31, 2020 due to the global emergence of COVID-19. However, during April and May 2020, as the infection rate of COVID-19 spread throughout New York and New Jersey, the governors of those states issued executive orders requiring residents, among other things, to remain at home with limited exceptions such as working at an essential business. Although as a pharmaceutical manufacturer Amneal is an essential business, we did experience supply chain constraints, including manufacturing and packaging delays at several of our key domestic manufacturing and packaging facilities in New York and New Jersey during the three months ended June 30, 2020. In June and July 2020, as the restrictions from the governors of New York and New Jersey were eased, our manufacturing and distribution facilities were able to resume normal productivity. However, we may again experience supply chain constraints at our New York, New Jersey, India or other facilities in the event of subsequent waves of COVID-19 infections. These potential supply chain disruptions may significantly impact our third and fourth quarter 2020 results of operations and cash flows. To mitigate any potential overall market liquidity constraints, we borrowed $300 million under our revolving credit facility in March 2020 as a precautionary measure. As the financial markets stabilized following a period of high volatility due the COVID-19 pandemic, we repaid all of the $300 million of borrowings under our revolving credit facility before June 30, 2020. (Refer to *Note 13. Debt,* for further details). As noted in our 2019 Annual Report on Form 10-K, several of our key domestic manufacturing, packaging, and facilities are located in New York and New Jersey, two states with a high number of confirmed cases of COVID-19. To offset the decreased second quarter output, we will increase production during the third and fourth quarters.

To the extent that the COVID-19 pandemic continues or worsens, national, state, and local governments may impose additional restrictions or extend the restrictions already in place. The worsening of the pandemic and the related safety and business operating restrictions could result in a number of adverse impacts to our business, including, but not limited to, additional disruption to the economy and our customers, additional work restrictions, and supply chains being interrupted or slowed. Also, governments may impose other laws, regulations, or taxes that could adversely impact our business, financial condition, or results of operations. Further, depending on the extent to which our customers are affected, they could delay or reduce purchases of products we provide. The potential effects of the COVID-19 pandemic also could impact us in a number of other ways including, but not limited to, reductions to our profitability, fluctuations in foreign currency markets, the availability of future borrowings, the cost of borrowings, credit risks of our customers and counterparties, and potential impairment of the carrying amount of goodwill or other definite-lived assets.

We will continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by national, state, or local authorities or that we determine are in the best interests of our employees, customers, partners, suppliers, and shareholders. Until the ultimate extent and duration of the pandemic is known, we cannot predict the ultimate effects the pandemic may have on our business, in particular with respect to demand for our products, our strategy, and our prospects, the effects on our customers, or the impact on our financial results. Refer to Part II, *Item 1A "Risk Factors"* of this Quarterly Report on Form 10-Q for further discussion of the potential impact of the COVID-19 pandemic on our business.

### Results of Operations

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three and six months ended June 30, 2020 and 2019 (in thousands):

|  | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $464,662 | $404,642 | $963,195 | $850,762 |
| Cost of goods sold | 319,666 | 296,381 | 633,244 | 606,124 |
| Cost of goods sold impairment charges | 759 | 3,012 | 2,215 | 56,309 |
| **Gross profit** | 144,237 | 105,249 | 327,736 | 188,329 |
| Selling, general and administrative | 80,944 | 67,281 | 158,920 | 151,717 |
| Research and development | 45,572 | 48,016 | 81,951 | 101,874 |
| In-process research and development impairment charges | — | — | 960 | 22,787 |
| Intellectual property legal development expenses | 3,550 | 2,511 | 4,820 | 6,677 |
| Acquisition, transaction-related and integration expenses | 1,787 | 3,519 | 4,362 | 9,551 |
| Charges related to legal matters, net | 1,300 | — | 5,800 | — |
| Restructuring and other charges | 333 | 2,835 | 2,381 | 8,996 |
| **Operating income (loss)** | 10,751 | (18,913) | 68,542 | (113,273) |
| Total other expense, net | (32,509) | (37,314) | (76,956) | (76,134) |
| Loss before income taxes | (21,758) | (56,227) | (8,414) | (189,407) |
| Provision for (benefit from) income taxes | 2,186 | (5,701) | (105,987) | (14,129) |
| **Net (loss) income** | $(23,944) | $(50,526) | $97,573 | $(175,278) |

#### Net Revenue

Net revenue for the three months ended June 30, 2020 increased by 15%, or $60 million, to $465 million as compared to $405 million for the three months ended June 30, 2019. The increase over the prior year is primarily attributable to $67 million from the Acquisitions, $39 million from new product launches after June 30, 2019 in our Generics segment and $12 million primarily from volume increases in our Specialty segment, which were partially offset by erosion in our Generics segment and a $2 million decline from the divestiture of our international business in Germany.

Net revenue for the six months ended June 30, 2020 increased by 13%, or $112 million, to $963 million as compared to $851 million for the six months ended June 30, 2019. The increase over the prior year is primarily attributable to $132 million from the Acquisitions, $101 million from new product launches after June 30, 2019 in our Generics segment and $20 million primarily from volume increases in our Specialty segment, which were partially offset by erosion in our Generics segment and a $16 million decline from the divestitures of our international businesses primarily in the U.K. and Germany.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold, including impairment charges, increased 7%, or $21 million, to $320 million for the three months ended June 30, 2020 as compared to $299 million for the three months ended June 30, 2019. The increase in cost of goods sold was primarily attributable to a $49 million increase associated with the Acquisitions, which were partially offset by a $15 million decline in inventory related charges, lower costs associated with sales erosion in our Generics segment, a $4 million decline in site closure expenses, and a $2 million decline associated with the divestiture of our international business in Germany.

Accordingly, gross profit for the three months ended June 30, 2020 was $144 million (31% of total net revenue) as compared to gross profit of $105 million (26% of total net revenue) for the three months ended June 30, 2019. Our gross profit as a percentage of net revenue increased compared to the prior year primarily as a result of the decline in inventory related charges.

Cost of goods sold, including impairment charges, decreased 4%, or $27 million, to $635 million for the six months ended June 30, 2020 as compared to $662 million for the six months ended June 30, 2019. The decrease in cost of goods sold was primarily attributable to a $54 million decrease in intangible asset impairments mainly in our Generics segment, a $36 million decrease in expenses related to the Levothyroxine transition agreement with Lannett Company ("Lannett"), a $16 million decline in inventory related charges, a $12 million decline in site closure expenses, lower costs associated with sales erosion in our Generics segment, and a $12 million decline associated with the divestitures of our international businesses primarily in the U.K. and Germany, which were partially offset by a $104 million increase associated with the Acquisitions.

Accordingly, gross profit for the six months ended June 30, 2020 was $328 million (34% of total net revenue) as compared to gross profit of $188 million (22% of total net revenue) for the six months ended June 30, 2019. Our gross profit as a percentage of net revenue increased compared to the prior year primarily as a result of the $54 million decline in intangible impairment charges, as well as other factors described above.

#### Selling, General, and Administrative

Selling, General, and Administrative (“SG&A”) expenses for the three months ended June 30, 2020 were $81 million, as compared to $67 million for the three months ended June 30, 2019. The $14 million increase from the prior year was primarily due to a $16 million increase associated with the Acquisitions.

SG&A expenses for the six months ended June 30, 2020 were $159 million, as compared to $152 million for the six months ended June 30, 2019. The $7 million increase from the prior year was primarily due to a $26 million increase associated with the Acquisitions, which were partially offset by cost savings associated with our restructuring and integration programs.

#### Research and Development

Research and development (“R&D”) expenses for the three months ended June 30, 2020 were $46 million, as compared to $48 million for the three months ended June 30, 2019. The $2 million decrease compared to the prior year is primarily attributable to cost savings in our Generics segment associated with the Company’s restructuring programs and the timing of expenses in 2020 due to generic product mix and delayed spending as a result of COVID-19.

R&D expenses for the six months ended June 30, 2020 were $82 million, as compared to $102 million for the six months ended June 30, 2019. The $20 million decrease compared to the prior year is primarily attributable to cost savings in our Generics segment associated with the Company’s restructuring programs and the timing of expenses in 2020 due to delayed spending as a result of COVID-19.

#### In-Process Research and Development Impairment Charges

We recognized in-process research and development impairment charges for the six months ended June 30, 2020 of $1 million as compared to $23 million for the six months ended June 30, 2019 (none in the three months ended June 30, 2020 and 2019).

For the six months ended June 30, 2020, the charges are primarily associated with two products. One of the products experienced a delay in its estimated launch date and the other product was canceled due to the withdrawal of our development partner.

For the six months ended June 30, 2019, the charges are primarily associated with two products in our Generics segment that were acquired as part of the Combination.

#### Intellectual Property Legal Development Expense

Intellectual property legal development expenses for the three months ended June 30, 2020 were $4 million as compared to $3 million for the three months ended June 30, 2019. Intellectual property legal development expenses for the six months ended June 30, 2020 were $5 million as compared to $7 million for the six months ended June 30, 2019. These costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

#### Acquisition, Transaction-Related and Integration Expenses

We recognized approximately $2 million of acquisition, transaction-related and integration expenses for the three months ended June 30, 2020 as compared to $4 million for the three months ended June 30, 2019. We recognized approximately $4 million of acquisition, transaction-related and integration expenses for the six months ended June 30, 2020 as compared to $10 million for the three months ended June 30, 2019.

For the three and six months ended June 30, 2020 acquisition, transaction-related and integration expenses were primarily related to systems integrations associated with the Combination and integration activities associated with the Acquisitions. The decreases from the prior year are primarily related to the substantial completion of integration activities related to the Combination.

#### Charges Related to Legal Matters, Net

For the three months ended June 30, 2020, we recorded net charges of $1 million for commercial legal proceedings and claims, of which a $3 million charge recorded in our Generics segment was partially offset by a $2 million gain in our Specialty segment.

For the six months ended June 30, 2020, we recorded net charges of $6 million for commercial legal proceedings and claims, which was primarily recorded in our Generics segment.

#### Restructuring and Other Charges

On July 10, 2019, we announced a plan to restructure our operations that is intended to reduce costs and optimize our organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, we expect to reduce our headcount by approximately 300 to 350 by December 31, 2020, primarily by ceasing manufacturing at our Hauppauge, NY facility.

Restructuring and other charges were $0.3 million and $2 million for the three and six months ended June 30, 2020, respectively. These charges primarily consisted of charges associated with cash severance and other benefits provided pursuant to our severance programs for former executives.

Restructuring and other charges for the three and six months ended June 30, 2019 were $3 million and $9 million, respectively. These charges primarily consisted of cash and other severance charges provided pursuant to our severance programs for employees at our Hayward, CA facility and other facilities as well as cash severance charges associated with the cost of benefits for former senior executives.

#### Other Expense, Net

Other expense, net was $33 million for the three months ended June 30, 2020, as compared to $37 million for the three months ended June 30, 2019. The decrease of $4 million was primarily attributable to a $7 million decline in interest expense as reductions in interest rates offset increased borrowings and a $2 million favorable impact from divestitures, partially offset by a $5 million unfavorable foreign currency impact.

Other expense, net was $77 million for the six months ended June 30, 2020, as compared to $76 million for the six months ended June 30, 2019. The increase of $1 million was primarily attributable to a $7 million unfavorable impact from divestitures and a $5 million unfavorable foreign currency impact, partially offset by a $11 million decline in interest expense as reductions in interest rates offset increased borrowings.

#### Provision For (Benefit From) Income Taxes

For the three months ended June 30, 2020 and 2019, the Company's provision for (benefit from) income taxes and effective tax rates were $2 million and (10.0%) and $(6) million and 10.1%, respectively. The year over year change is primarily associated with an increase in foreign based earnings.

For the six months ended June 30, 2020 and 2019, the Company's benefit from income taxes and effective tax rates were ($106) million and 1259.7% and ($14) million and 7.5%, respectively. The year over year change is primarily associated with the $110 million benefit from the carryback of U.S. Federal deferred tax assets under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). In July 2020, we received $106 million in cash from U.S. federal tax refunds associated with the CARES Act, with the remaining $4 million in cash refunds expected to be received before December 31, 2020. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic which, among other things, includes provisions relating to income and non-income-based tax laws. These deferred tax assets had a 100% valuation allowance as of December 31, 2019.

#### Net (Loss) Income

We recognized a net loss for the three months ended June 30, 2020 of $24 million as compared to net loss of ($51) million for the three months ended June 30, 2019. The year over year decrease in our net loss of $27 million is primarily attributable to favorable gross profit of $39 million and a decline in interest expense of $7 million, partially offset by an increase in selling, general and administrative expenses associated with the Acquisition of $16 million, a decrease in foreign exchange gains of $5 million and an increase in the provision for income taxes of $8 million.

We recognized net income for the six months ended June 30, 2020 of $98 million as compared to net loss of ($175) million for the six months ended June 30, 2019. The year over year increase of $273 million is primarily attributable to favorable gross profit of $139 million (including a $54 million decline of intangible asset impairment charges and a $36 million decrease in expenses related to the Levothyroxine transition agreement with Lannett), a $92 million favorable impact from income taxes related to the CARES Act, a $22 million decline in IPR&D impairment charges and $11 million from lower interest expense.

### Generics

The following table sets forth results of operations for our Generics segment for the three and six months ended June 30, 2020 and 2019 (in thousands):

|  | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $306,559 | $335,064 | $659,145 | $717,541 |
| Cost of goods sold | 218,909 | 263,423 | 437,774 | 542,301 |
| Cost of goods sold impairment charges | 759 | 3,012 | 2,215 | 56,309 |
| **Gross profit** | 86,891 | 68,629 | 219,156 | 118,931 |
| Selling, general and administrative | 12,802 | 14,379 | 29,425 | 38,527 |
| Research and development | 40,316 | 45,448 | 69,350 | 95,599 |
| In-process research and development impairment charges | — | — | 960 | 22,787 |
| Intellectual property legal development expenses | 3,550 | 2,511 | 4,815 | 5,632 |
| Charges related to legal matters | 3,050 | — | 5,550 | — |
| Other operating expenses | 657 | 1,405 | 703 | 6,083 |
| **Operating income (loss)** | $26,516 | $4,886 | $108,353 | $(49,697) |

#### Net Revenue

Generics net revenue was $307 million for the three months ended June 30, 2020, a decrease of $29 million or 9% when compared with the same period in 2019. The year over year decrease was primarily driven by erosion in our existing business primarily from Levothyroxine and Diclofenac Gel generic competition, a $13 million decline from the reclassification of Oxymorphone to our Specialty segment, and a $2 million decline from the divestiture of our international business in Germany, partially offset by $39 million from new product launches after June 30, 2019, which included EluRyng and Sucralfate Oral Suspension.

Generics net revenue was $659 million for the six months ended June 30, 2020, a decrease of $58 million or 8% when compared with the same period in 2019. The year over year decrease was primarily driven by erosion in our existing business primarily from Levothyroxine and Diclofenac Gel generic competition, a $26 million decline from the reclassification of Oxymorphone to our Specialty segment, and a $16 million decline from the divestitures of our international businesses primarily in the U.K. and Germany, partially offset by $101 million from new product launches after June 30, 2019, which included EluRyng and Sucralfate Oral Suspension.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold, including impairment charges, for the three months ended June 30, 2020 was $220 million, a decrease of 18% or $47 million compared to the three months ended June 30, 2019. The year over year decrease was primarily associated with a $15 million decline in inventory related charges, a $9 million decline in royalty expense primarily associated with the reclassification of Oxymorphone, a $4 million decline in amortization expense, a decrease of $4 million in site closure expenses, a $2 million decline in intangible asset impairment charges, and a $2 million decline associated with the divestiture of our international business in Germany.

Generics gross profit for the three months ended June 30, 2020 was $87 million (28% of Generics net revenue) as compared to gross profit of $69 million (20% of Generics net revenue) for the three months ended June 30, 2019. Our Generics gross profit as a percentage of sales increased compared to the prior year period primarily as a result of the factors described above.

Generics cost of goods sold, including impairment charges, for the six months ended June 30, 2020 was $440 million, a decrease of 26% or $159 million compared to the six months ended June 30, 2019. The year over year decrease was primarily associated with a $54 million decline in intangible asset impairment charges. Cost of goods sold was also favorably impacted by a $36 million decline of expenses related to the Levothyroxine transition agreement with Lannett, a $16 million decline in inventory related charges, a $12 million decline in site closure expenses, a $12 million decline associated with the divestitures of our international businesses primarily in the U.K and Germany and a $4 million decline in amortization expense.

Generics gross profit for the six months ended June 30, 2020 was $219 million (33% of Generics net revenue) as compared to gross profit of $119 million (17% of Generics net revenue) for the six months ended June 30, 2019. Our Generics gross profit as a percentage of sales increased compared to the prior year period primarily as a result of the $54 million decline in impairment charges and the other factors described above.

#### Selling, General, and Administrative

Generics SG&A expense for the three months ended June 30, 2020 was $13 million, as compared to $14 million for the three months ended June 30, 2019. The $1 million year over year decrease was primarily associated with cost savings initiatives associated with our restructuring and integration programs and the timing of expenses in 2020 due to delayed spending as a result of COVID-19.

Generics SG&A expense for the six months ended June 30, 2020 was $29 million, as compared to $39 million for the six months ended June 30, 2019. The $10 million year over year decrease was primarily associated with cost savings initiatives associated with our restructuring and integration programs and the timing of expenses in 2020 due to delayed spending as a result of COVID-19 and a reduction in international expenditures.

#### Research and Development

Generics R&D expenses for the three months ended June 30, 2020 was $40 million, a decrease of 11% or $5 million compared to the three months ended June 30, 2019. The year over year decrease is primarily associated with cost savings associated with our restructuring program, delays from COVID-19 and transitioning some third party costs in-house.

Generics R&D expenses for the six months ended June 30, 2020 was $69 million, a decrease of 27% or $26 million compared to the six months ended June 30, 2019. The year over year decrease is primarily associated with cost savings associated with our restructuring programs, delays from COVID-19 and transitioning some third party costs in-house.

#### In-Process Research and Development Impairment Charges

We recognized IPR&D impairment charges of $1 million for the six months ended June 30, 2020 as compared to $23 million for the six months ended June 30, 2019 (none for the three months ended June 30, 2020 and 2019).

For the six months ended June 30, 2020, the charges are primarily associated with two products. One of the products experienced a delay in its estimated launch date and the other product was canceled due to the withdrawal of our development partner.

For the six months ended June 30, 2019, the charges are primarily associated with two products that were acquired as part of the Combination.

#### Charges Related to Legal Matters

For the three and six months ended June 30, 2020, we recorded charges of approximately $3 million and $6 million, respectively, for commercial legal claims (none for the three and six months ended June 30, 2019).

#### Intellectual Property Legal Development Expenses

Generics intellectual property legal development expenses for the three months ended June 30, 2020 were $4 million as compared to $3 million for the prior year period. Generics intellectual property legal development expenses for the six months ended June 30, 2020 were $5 million as compared to $6 million for the prior year period.

These costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

#### Other Operating Expenses

For the three months ended June 30, 2020 and 2019, other operating expenses were not material.

For the six months ended June 30, 2020, other operating expenses were not material. For the six months ended June 30, 2019, we recorded $6 million of other operating expenses. These expenses were primarily attributable to integration expenses associated with the Combination.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three and six months ended June 30, 2020 and 2019 (in thousands):

|  | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $94,256 | $69,578 | $182,233 | $133,221 |
| Cost of goods sold | 50,229 | 32,958 | 98,047 | 63,823 |
| **Gross profit** | 44,027 | 36,620 | 84,186 | 69,398 |
| Selling, general and administrative | 16,870 | 16,150 | 37,812 | 37,477 |
| Research and development | 5,256 | 2,568 | 12,601 | 6,275 |
| Intellectual property legal development expenses | — | — | 5 | 1,045 |
| (Gains) charges related to legal matters, net | (1,750) | — | 250 | — |
| Other operating expenses | 82 | 1,366 | 82 | 3,428 |
| **Operating income** | $23,569 | $16,536 | $33,436 | $21,173 |

#### Net Revenue

Specialty net revenue for the three months ended June 30, 2020 was $94 million, an increase of 35% or $25 million compared to the three months ended June 30, 2019. The increase from the prior year period was primarily due to $13 million from the reclassification of Oxymorphone from our Generics segment as well as a $12 million increase in our existing business primarily associated with volume increases in Oxymorphone and Rytary.

Specialty net revenue for the six months ended June 30, 2020 was $182 million, an increase of 37% or $49 million compared to the six months ended June 30, 2019. The increase from the prior year period was primarily due to $26 million from the reclassification of Oxymorphone from our Generics segment as well as a $20 million increase in our existing business primarily associated with volume increases in Oxymorphone, Rytary and Unithroid.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended June 30, 2020 was $50 million, an increase of $17 million or 52% compared to the three months ended June 30, 2019. The increase from the prior year period was primarily due to $11 million of incremental expenses associated with the reclassification of Oxymorphone and $5 million of incremental amortization expense, as well as a volume increase in our existing business.

Accordingly, Specialty gross profit for the three months ended June 30, 2020 was $44 million (47% of Specialty net revenue) as compared to gross profit of $37 million (53% of Specialty net revenue) for the three months ended June 30, 2019.

Specialty cost of goods sold for the six months ended June 30, 2020 was $98 million, an increase of $34 million or 54% compared to the six months ended June 30, 2019. The increase from the prior year period was primarily due to $20 million of incremental expenses associated with the reclassification of Oxymorphone and $10 million of incremental amortization expense, as well as a volume increase in our existing business.

Accordingly, Specialty gross profit for the six months ended June 30, 2020 was $84 million (46% of Specialty net revenue) as compared to gross profit of $69 million (52% of Specialty net revenue) for the six months ended June 30, 2019.

#### Selling, General, and Administrative

Specialty SG&A expense of $17 million and $38 million for the three and six months ended June 30, 2020, respectively, was flat with the prior year periods.

#### Research and Development

Specialty R&D expenses for the three months ended June 30, 2020 were $5 million, as compared to $3 million for the three months ended June 30, 2019. The $2 million increase from the prior year period was primarily due to an increase in development costs for IPX203.

Specialty R&D expenses for the six months ended June 30, 2020 were $13 million, as compared to $6 million for the six months ended June 30, 2019. The $7 million increase from the prior year period was primarily due to an increase in development for IPX203 and a $2 million milestone achievement of one of our development partners.

#### (Gains) Charges Related to Legal Matters, Net

For the three months ended June 30, 2020, we recorded a gain of $2 million for the favorable resolution of a commercial legal proceeding.

#### Other Operating Expenses

For the three and six months ended June 30, 2019, other operating expenses of $1 million and $3 million, respectively, were primarily attributable to integration expenses associated with the Combination.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the three and six months ended June 30, 2020 (in thousands):

|  | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $63,847 | $— | $121,817 | $— |
| Cost of goods sold | 50,528 | — | 97,423 | — |
| **Gross profit** | 13,319 | — | 24,394 | — |
| Selling, general and administrative | 15,647 | — | 26,435 | — |
| **Operating loss** | $(2,328) | $— | $(2,041) | $— |

Our AvKARE segment consists of the businesses we acquired in the Acquisitions on January 31, 2020. Prior to the Acquisitions, we did not have an AvKARE segment. Refer to *Note 3. Acquisitions and Divestitures.*

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash and borrowings under debt financing arrangements, including $414 million of available additional capacity on our Revolving Credit Facility as of July 16, 2020, as defined below. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations and provide sufficient liquidity over the next 12 months. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, the impact of the COVID-19 pandemic, and demand for our products, which are factors that may be out of our control.

Our primary uses of capital resources are to fund operating activities, including research and development expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, and spending on production facility expansions and capital equipment items. As the impact of the COVID-19 pandemic on the economy and our operations evolves, we will continue to assess our liquidity needs. A continued worldwide disruption could materially affect our future access to sources of liquidity, particularly our cash flows from operations, and financial condition. In the event of a sustained market deterioration, we may need additional liquidity, which would require us to evaluate available alternatives and take appropriate actions.

On March 27, 2020, President Trump signed into law the CARES Act. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic which, among other things, includes provisions relating to income and non-income-based tax laws. In July 2020, we received $106 million in cash from U.S. federal tax refunds associated with the CARES Act (refer to *Note 8. Income Taxes*) with an additional $4 million in cash refunds expected to be received before December 31, 2020. Other non-income-based tax provisions include deferral of the employer share of Social Security payroll taxes due from the CARES Act date of enactment through December 31, 2020, and a potential 50% credit on qualified wages against employment taxes each quarter with any excess credits eligible for refunds.

Over the next 12 months, we will make substantial payments for monthly interest and quarterly principal amounts due on our term loans, Revolving Credit Facility, severance and capital expenditures.

We are party to a tax receivable agreement that requires us to make cash payments to APHC Holdings LLC (formerly known as Amneal Holdings LLC) ("Holdings") in respect of certain tax benefits that we may realize or may be deemed to realize as a result of sales or exchanges of Amneal common units by Holdings. The timing and amount of any payments under the TRA will also vary, depending upon a number of factors including the timing and number of Amneal common units sold or exchanged for our Class A Common Stock, the price of our Class A Common Stock on the date of sale or exchange, the timing and amount of our taxable income, and the tax rate in effect at the time of realization of our taxable income. The tax receivable agreement also requires that we make an accelerated payment to Holdings equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. Further sales or exchanges occurring subsequent to June 30, 2020 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal common units. These obligations could be incremental to and substantially larger than the approximate $202 million contingent liability as of June 30, 2020 (refer to *Note 8. Income Taxes*). Payments could also be in excess of the tax savings that we ultimately realize. Because of the foregoing, our obligations under the tax receivable agreement could have a substantial negative impact on our liquidity. For further details, see *Item 1A. Risk Factors* and *Note 8. Income Taxes* in our 2019 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, in connection with any tax period, Amneal will be required to make distributions to its members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than the Company) has received an amount at least equal to its assumed tax liability and the Company has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the tax receivable agreement. For the three months ended June 30, 2020, no cash tax distributions were made to Holdings. In July 2020, we made cash tax distributions of $1 million to Holdings pursuant to the limited liability operating agreement.

At June 30, 2020, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the United States. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the United States may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

#### (in thousands)

| Cash provided by (used in): | Six Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: |
| Operating activities | $228,267 | $(87,316) |
| Investing activities | (270,969) | (44,795) |
| Financing activities | 157,897 | (30,939) |
| Effect of exchange rate changes on cash | 255 | 1,293 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $115,450 | $(161,757) |

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $228 million for the six months ended June 30, 2020 compared to net cash used in operating activities of $(87) million for the six months ended June 30, 2019. The change was primarily attributed to improved operating performance, favorable timing impacts from the collections of trade receivables and payments of accounts payable and accrued expenses, and a decrease in payments of employee separation benefits and interest, which were partially offset by an unfavorable impact from income taxes.

#### Cash Flows from Investing Activities

The increase in cash used in investing activities of $226 million for the six months ended June 30, 2020 compared to the six months ended June 30, 2019, was primarily related to cash paid for the Acquisitions, partially offset by a decrease in proceeds from sale of international businesses and decreases in purchases of property, plant and equipment and acquisitions of intangible assets.

#### Cash Flows from Financing Activities

Net cash provided by financing activities was $158 million for the six months ended June 30, 2020 compared to net cash used in financing activities of ($31) million for the six months ended June 30, 2019. The change was primarily attributable to the net proceeds from a $180 million term loan associated with the Acquisitions and a decrease in tax distributions to non-controlling interests.

### Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in the Company’s 2019 Annual Report on Form 10-K. Other than the contractual obligations noted below, there have been no material changes to the disclosure presented in our 2019 Annual Report on Form 10-K.

| Contractual Obligations | Payments Due by Period (in thousands) Total | Less Than 1 Year | 1-3 Years | 3-5 Years | More Than 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Rondo Term Loan (1) | $177,750 | $4,500 | $18,000 | $18,000 | $137,250 |
| Interest payments on Rondo Term Loan (2) | 34,383 | 4,214 | 15,651 | 13,966 | 552 |

(1) Rondo Term loan relates to the Acquisitions.

(2) Interest on the Rondo Term Loan was calculated based on the applicable rate at June 30, 2020.

The foregoing table does not include the $45 million of aggregate principal and the related interest due on the long-term promissory notes (“Sellers Notes”) and the short-term promissory note (“Short-Term Sellers Note”) issued in connection with the Acquisition because of the uncertainty as to when those amounts will be repaid. Refer to the section *Acquisition Financing – Notes Payable-Related Party* below for additional information.

### Levothyroxine License and Supply Agreement; Transition Agreement

On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. ("JSP") for Levothyroxine. This agreement designated the Company as JSP's exclusive commercial partner for Levothyroxine in the U.S. market for a 10-year term commencing on March 22, 2019. Under this license and supply agreement with JSP, the Company accrued the up-front license payment of $50 million on March 22, 2019, which was paid in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs.

On November 9, 2018, the Company entered into a transition agreement ("Transition Agreement") with Lannett and JSP. Under the terms of the Transition Agreement, the Company assumed the distribution and marketing of Levothyroxine from Lannett beginning December 1, 2018 through March 22, 2019, ahead of the commencement date of the license and supply agreement with JSP described above.

In accordance with the terms of the Transition Agreement, the Company made $47 million of non-refundable payments to Lannett. For the six months ended June 30, 2019, $37 million (none in 2020) were expensed to cost of goods sold, as the Company sold Levothyroxine. As of December 31, 2018, the Company had a $4 million transition contract liability, which was fully settled in February 2019.

Additionally, during the year ended December 31, 2019, the Company recorded $1 million in cost of sales related to reimbursement due to Lannett for certain of its unsold inventory at the end of the Transition Period, which was fully settled in March 2020.

### Outstanding Debt Obligations

### Senior Secured Credit Facilities

On May 4, 2018 we entered into a senior credit agreement that provided a term loan (“Term Loan”) with a principal amount of $2.7 billion and an asset backed revolving credit facility (“Revolving Credit Facility”) under which loans and letters of credit up to a principal amount of $500 million, on which $414 million are available (principal amount of up to $25 million is available for letters of credit) (collectively, the "Senior Secured Credit Facilities"). The Term Loan is repayable in equal quarterly installments at a rate of 1.00% or the original principal amount annually, with the balance payable at maturity on May 4, 2025. The Term Loan bears a variable annual interest rate, which is one-month LIBOR plus 3.5% at June 30, 2020. The Revolving Credit Facility bears an annual interest rate of one-month LIBOR plus 1.25% at June 30, 2020 and matures on May 4, 2023. The annual interest rate for the Revolving Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the average historical excess availability.

The proceeds of any loans made under the Senior Secured Credit Facilities can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. We pay a commitment fee based on the average daily unused amount of the Revolving Credit Facility at a rate based on average historical excess availability, between 0.25% and 0.375% per annum. At June 30, 2020, the Revolving Credit Facility commitment fee rate is 0.375% per annum.

During March 2020, as a precautionary measure to mitigate the uncertainty surrounding overall market liquidity due to COVID-19, we borrowed $300 million on the Revolving Credit Facility. At June 30, 2020, all $300 million was repaid.

The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal's and its subsidiaries' assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries' ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The Revolving Credit Facility also includes a financial covenant whereby Amneal must maintain a minimum fixed charge coverage ratio if certain borrowing conditions are met. The Senior Secured Credit Facilities contain customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. At June 30, 2020, Amneal was in compliance with all covenants under the Senior Secured Credit Facilities.

### Acquisition Financing – Revolving Credit and Term Loan Agreement

On January 31, 2020, in connection with the Acquisitions, Rondo Intermediate Holdings, LLC (“Rondo Holdings”), a wholly-owned subsidiary of Rondo, entered into a revolving credit and term loan agreement (“Rondo Credit Facility”) that provided a term loan ("Rondo Term Loan") with a principal amount of $180 million and a revolving credit facility (“Rondo Revolving Credit Facility”) which loans up to a principal amount of $30 million. The Rondo Term Loan is repayable in equal quarterly installments at a rate of 5.0% of the original principal amount annually, with the balance payable at maturity on January 31, 2025. The Rondo Credit Facility bears a variable annual interest rate, which is one-month LIBOR plus 3.0% at June 30, 2020 and matures on January 31, 2025. The annual interest rate for borrowing under the Rondo Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the total net leverage ratio, as defined in that agreement. At June 30, 2020, the Company had no outstanding borrowings under the Rondo Revolving Credit Facility.

A commitment fee based on the average daily unused amount of the Rondo Credit Facility is assessed at a rate based on total net leverage ratio, between 0.25% and 0.50% per annum. At June 30, 2020, the Rondo Credit Facility commitment fee rate is 0.4% per annum.

The Rondo Credit Facility contains a number of covenants that, among other things, create liens on the equity securities and assets of Rondo Holdings, Rondo, AvKARE, LLC and R&S. The Rondo Credit Facility contains certain negative, affirmative and financial covenants that, among other things, restrict the ability to incur additional debt, grant liens, transact in mergers and acquisitions, make certain investments and payments or engage in certain transactions with affiliates. The Rondo Credit Facility also contains customary events of default. Upon the occurrence of certain events of default, the obligations under the Rondo Credit Facility may be accelerated and/ or the interest rate may be increased. At June 30, 2020, Rondo was in compliance with all covenants. The Company is not party to the Rondo Credit Facility and is not a guarantor of any debt incurred thereunder.

### Acquisition Financing – Notes Payable-Related Party

The Sellers Notes with a stated principal amount of $44 million and the Short-Term Sellers Note with a stated principal amount of $1 million were issued by Rondo or its subsidiary, Rondo Top Holdings, LLC, on January 31, 2020, the closing date of the Acquisitions. The Sellers Notes are unsecured and accrue interest at a rate of 5% per annum, not compounded, until June 30, 2025. The Sellers Notes are subject to prepayment at the option of Rondo, as the obligor, without premium or penalty. Mandatory payment of the outstanding principal and interest is due on June 30, 2025 if certain financial targets are achieved, the borrowers’ cash flows are sufficient (as defined in the Sellers Notes) and repayment is not prohibited by senior debt. If repayment of all outstanding principal and accrued interest on the Sellers Notes is not made on June 30, 2025, the requirements for repayment are revisited on June 30 of each subsequent year until all principal and accrued interest on the Sellers Notes are satisfied no later than January 31, 2030 or earlier, upon a change in control. The Short-Term Sellers Note is also unsecured and accrues interest at a rate of 1.6% and is due on January 31, 2020.

The Sellers Notes were recorded at a fair value of $35 million, which was estimated using the Monte-Carlo simulation approach under the option pricing framework. The Short-Term Sellers Note of $1 million was recorded at the stated principal amount of $1 million, which approximates fair value. The $9 million discount on the Sellers Notes will be amortized to interest expense using the effective interest method from January 31, 2020 to June 30, 2025 as the carrying value of the Sellers Notes will accrete to the stated principal amount of $44 million.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30, 2020.

### Critical Accounting Policies

For a discussion of the Company’s critical accounting policies, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2019 Annual Report on Form 10-K. There have been no material changes to the disclosure presented in our 2019 Annual Report on Form 10-K.

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 2. Summary of Significant Accounting Policies.*

## Market risk

As filed, 198 characters.

There has not been any material change in our assessment of market risk as set forth in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk*, in our 2019 Annual Report on Form 10-K.

## Controls and procedures

As filed, 4,771 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this

Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that due to the material weakness, described below, our disclosure controls and procedures were not effective as of June 30, 2020.

The material weakness in internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) resulted from ineffective controls over cash disbursements. Specifically, we did not have adequate controls to prevent improper changes to banking information in our vendor master file, which allowed cash disbursements to be redirected from a vendor bank account to an unrelated bank account. In light of the material weakness, we performed additional analysis, including validating changes to vendor bank account information made during 2020, to ensure that the Company’s financial statements covered by this Quarterly Report on Form 10-Q are prepared in accordance with generally accepted accounting principles in the United States of America.

This control deficiency did not result in any financial loss or any material impact to the financial statements for the periods covered by this Quarterly Report on Form 10-Q or for any prior periods.

To remediate the material weakness described above, we have enhanced the design and execution of our existing controls and procedures to prevent improper changes to the banking information in our vendor master file. We expect that remediation will be completed prior to December 31, 2020 following sufficient operational time for the applicable remedial controls and subsequent testing.

### Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2020, except as noted above, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Systems of disclosure controls and internal controls over financial reporting and their associated policies and procedures, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the system of control are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide a reasonable assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.

## Risk factors

As filed, 9,908 characters.

Other than as set forth below, there have been no material changes to the disclosures presented in our 2019 Annual Report on Form 10-K under *Item 1A. Risk Factors.* The direct and indirect impact of the COVID-19 pandemic could also affect or amplify one or more of the risk factors included in our 2019 Annual Report on 10-K. However, given the unpredictable, unprecedented and fluid nature of the pandemic, the potential impacts it could have on us, whether direct or indirect, remain uncertain. Additionally, other risks that we do not presently perceive or that we currently believe are not material may also adversely affect us.

***If we fail to maintain an effective system of internal control over financial reporting, or to remediate any existing material weakness, we may not be able to accurately report our financial results, timely file our periodic reports, maintain our reporting status or prevent fraud.***

We are required to comply with Section 404 of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires public companies to conduct an annual review and evaluation of their internal controls and attestations of the effectiveness of internal controls by independent auditors. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. Our failure to maintain the effectiveness of our internal controls in accordance with the requirements of the Sarbanes-Oxley Act or to remediate any identified material weaknesses, or the inability of our independent registered public accounting firm to express an opinion as to the effectiveness of our internal control over financial reporting, could have a material adverse effect on our business. We could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on the price of our common stock. In addition, if our efforts to comply with new or changed laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

In connection with the preparation of our condensed consolidated financial statements for the three and six months ended June 30, 2020, our management identified a material weakness in internal controls over financial reporting regarding cash disbursements, as discussed in greater detail in Part I, *Item 4 "Controls and Procedures."* Our management or our independent registered public accounting firm may also identify material weaknesses in our internal control over financial reporting in the future. The existence of the existing material weakness or any future internal control material weaknesses may result in current and potential stockholders and alliance and collaboration agreements’ partners losing confidence in our financial reporting, which could harm our business, the market price of our common stock, and our ability to retain our current, or obtain new, alliance and collaboration agreements’ partners. Further, we may not be successful in making the improvements necessary to remediate the existing or any future material weakness, or in doing so in a timely and cost-effective manner.

In addition, the existence of material weaknesses in our internal control over financial reporting may affect our ability to timely file periodic reports under the Exchange Act. The inability to timely file periodic reports under the Exchange Act could result in the SEC revoking the registration of our common stock, which would prohibit us from listing or having our stock quoted on any public market. This would have an adverse effect on our business and stock price by limiting the publicly available information regarding us and greatly reducing the ability of our stockholders to sell or trade our common stock.

***The spread of the novel coronavirus (“COVID-19”) pandemic and other adverse public health developments could adversely affect our business and results of operations.***

On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of non-essential services. These measures, though currently temporary in nature, may become more severe and continue indefinitely depending on the evolution of the COVID-19 pandemic. To date, no fully effective vaccines or treatments have been developed and effective vaccines or treatments may not be discovered soon enough to protect against a worsening of the outbreak or to prevent COVID-19 from becoming endemic.

Our business and results of operations could be materially adversely affected by the COVID-19 pandemic. In particular, the COVID-19 pandemic could materially adversely impact the Company's operations, including, among other things, its manufacturing operations, supply chain, sales and marketing and clinical trial operations. Any of these factors could adversely affect the Company's business, operating results or financial condition. The United States, India and China, three countries particularly hard hit by the pandemic, represent vital aspects of our direct and indirect supply chain and the United States is the largest end market for our products, representing the geographic source of almost our entire 2019 net revenue. We have taken precautionary measures intended to help minimize the risk of the virus to our employees, including requiring non-production employees to work remotely, suspending all non-essential travel worldwide, and restricting or prohibiting attendance at industry events and in-person work-related meetings. While these measures are temporary, they may continue until the pandemic is contained. The spread of COVID-19 could also negatively affect the operations of the third parties with whom we do business, including our raw material providers, aspects of our supply chain and our development, collaboration and commercial partners, for the same or different reasons that it is impacting our business directly. We expect the foregoing and other unanticipated challenges will cause delays or disruptions in the manufacture, supply and availability of our products, particularly those in New York and New Jersey and more generally will make it more difficult to operate our business. Any of these factors could adversely affect the Company's business, operating results or financial condition.

The spread of COVID-19 could also adversely affect our clinical trial operations and other research and development activities in the United States and elsewhere, including our ability to recruit and retain volunteers, principal investigators and site staff who, as patients and healthcare providers, may have heightened exposure risks and sensitivities to COVID-19. Further, some patients may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services or may become infected with COVID-19 themselves, any of which would delay our ability to conduct clinical trials or release clinical trial results. COVID-19 may also affect employees of third-party contract research organizations that we rely upon to carry out our clinical trials, which could result in inefficiencies due to reductions in staff and disruptions to work environments. The outbreak could impact the day-to-day operations of the FDA and other health authorities in their ability to respond to non-emergency matters, which could delay reviews and approvals of product candidates.

The COVID-19 pandemic has adversely affected many industries as well as the economies and financial markets of many countries, including the United States, India and China, resulting in a significant deceleration of economic activity. This slowdown has reduced production, decreased the level of trade, and led to widespread corporate downsizing, causing a sharp increase in unemployment. We have also seen significant disruption of and extreme volatility in the global capital markets, which could increase the cost of, or entirely restrict access to, capital. This volatility and uncertainty have adversely affected our stock price and may continue to do so. The impact of this pandemic on the U.S., Indian, Chinese and world economies is uncertain and, unless the pandemic is contained, these adverse impacts could worsen, impacting all segments of the global economy, and result in a significant recession or worse.

Considerable uncertainty still surrounds the COVID-19 virus and its potential effects, and the extent of and effectiveness of any responses taken on a local, national and global level. Infections may become more widespread and that could accelerate or magnify one or more of the risks described above. While we expect the COVID-19 pandemic and related events will have a negative effect on our business, the full extent and scope of the impact on national, regional and global markets and economies, and therefore our business and industry, is highly uncertain and cannot be predicted. Accordingly, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, any of which could have a material adverse impact on our business and our results of operation and financial condition.

Filed Aug 6, 2020.
Source: SEC EDGAR, the filing index for accession 0001723128-20-000013. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
